Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: AMRN stock price vs PAYC: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at PAYC's multiple
Needs PAYC P/S.
Implied fair value · at AMRN's multiple
Needs AMRN P/S.
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: AMRN FY 2025 (ended Dec 31, 2025) · PAYC FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
AMARIN CORP PLC\UK · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Paycom Software, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.39x
3.03x
Net debt / EBITDA
Leverage against operating earnings
3.79x
6.56x
Cash and equivalents
Liquid reserves on the balance sheet
$302.59M
$370.00M
Total debt
Interest-bearing obligations outstanding
$177.39M
$5.25B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LIGAND PHARMACEUTICALS INC
AMRN vs LGND
Harmony Biosciences Holdings, Inc.
AMRN vs HRMY
SUPERNUS PHARMACEUTICALS, INC.
AMRN vs SUPN
Viatris Inc
AMRN vs VTRS
Organon & Co.
AMRN vs OGN
INCYTE CORP
AMRN vs INCY
AUTOMATIC DATA PROCESSING INC
AMRN vs ADP
PAYCHEX INC
AMRN vs PAYX
INTUIT INC.
AMRN vs INTU
Autodesk, Inc.
AMRN vs ADSK
TYLER TECHNOLOGIES INC
AMRN vs TYL
Salesforce, Inc.
AMRN vs CRM
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
